Kodiak’s Zenkuda Improves DRSS by 62.5% and Cuts Complication Risk by 85%
In GLOW2, 62.5% of Zenkuda patients achieved ≥2-step DRSS improvement versus 3.3% with sham (p<0.0001) and 13.7% reached ≥3-step improvement versus 0% (p<0.0001). The therapy reduced sight-threatening complication risk by 85% (2.4% vs 15.8%, p=0.0001), showed 0% intraocular inflammation and 2.3% cataract rate, and has a BLA-ready profile.
1. Trial Design and Patient Population
GLOW2 was a confirmatory Phase 3 study enrolling treatment-naïve patients with mild to proliferative diabetic retinopathy and center-involving diabetic macular edema. Patients were randomized to intravitreal Zenkuda or sham injections at baseline, Weeks 4, 8, 20 and 44, achieving a six-month dosing interval by Week 44.
2. Primary and Key Secondary Efficacy Results
Zenkuda met its primary endpoint with 62.5% of patients achieving at least a two-step improvement in DRSS versus 3.3% for sham (p<0.0001) and 13.7% achieving a three-step improvement versus 0% (p<0.0001). The therapy also delivered an 85% reduction in sight-threatening complications (2.4% vs 15.8%, p=0.0001).
3. Safety and Tolerability Profile
Zenkuda demonstrated a favorable safety profile with no intraocular inflammation and a 2.3% cataract incidence compared to 1.6% with sham. No cases of retinal vasculitis or occlusive retinal vasculitis were observed, supporting the tolerability of the ABC® biopolymer conjugate formulation.
4. Regulatory and Commercial Outlook
Driven by these robust efficacy and safety outcomes, Kodiak plans to accelerate its multi-indication Biologics License Application for Zenkuda in diabetic retinopathy. The six-month dosing interval and confirmed durability underpin its potential to transform standard care for a broad diabetic population.